Bispecific Therapy for Relapsed/Refractory Multiple Myeloma

Learn how to spot myeloma progression, distinguish relapse vs refractory disease, and decide when to treat—especially after lenalidomide maintenance and biochemical relapse.

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse strategies like BCMA CAR-T and genomic profiling.

Track myeloma treatment shift to quadruplets, MRD-guided goals, and relapse strategies including CAR-T and genomic testing for longer survival.

For early relapsed myeloma, see how patient, disease, and prior therapy guide choices—and why teclistamab plus daratumumab shows standout PFS.